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Polymerases have a structurally highly conserved negatively charged
amino acid motif that is strictly required for Mg2+ cation-depen-
dent catalytic incorporation of (d)NTP nucleotides into nucleic
acids. Based on these characteristics, a nucleoside monophospho-
nate scaffold, α-carboxy nucleoside phosphonate (α-CNP), was
designed that is recognized by a variety of polymerases. Kinetic,
biochemical, and crystallographic studies with HIV-1 reverse tran-
scriptase revealed that α-CNPs mimic the dNTP binding through
a carboxylate oxygen, two phosphonate oxygens, and base-pair-
ing with the template. In particular, the carboxyl oxygen of the
α-CNP acts as the potential equivalent of the α-phosphate oxygen
of dNTPs and two oxygens of the phosphonate group of the α-CNP
chelate Mg2+, mimicking the chelation by the β- and γ-phosphate
oxygens of dNTPs. α-CNPs (i) do not require metabolic activation
(phosphorylation), (ii) bind directly to the substrate-binding site,
(iii) chelate one of the two active site Mg2+ ions, and (iv) reversibly
inhibit the polymerase catalytic activity without being incorpo-
rated into nucleic acids. In addition, α-CNPs were also found to
selectively interact with regulatory (i.e., allosteric) Mg2+-dNTP-bind-
ing sites of nucleos(t)ide-metabolizing enzymes susceptible to met-
abolic regulation. α-CNPs represent an entirely novel and broad
technological platform for the development of specific substrate
active- or regulatory-site inhibitors with therapeutic potential.
(deoxy)nucleoside triphosphate mimic | HIV reverse transcriptase |
herpes virus DNA polymerase | allosteric inhibition | alpha-carboxy
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Awide variety of proteins and enzymes specifically recognize(2’-deoxy)nucleoside 5′-triphosphates [(d)NTPs]. Nucleic
acid polymerases are among the best known examples, and HIV-
encoded reverse transcriptase (RT) is perhaps the best studied
and established enzyme in this regard.
The polymerization of nucleotides by Escherichia coli DNA
polymerase I represents a general model for catalytic action of
nucleic acid polymerases (SI Appendix, Fig. S1) (1, 2). According
to this model, there is a universal role for the Mg2+ cation to
interact with three phosphate oxygens of dNTP. The highly
conserved consensus motifs in every polymerase active site
consist of either aspartate or glutamate residues that chelate
Mg2+ through three additional coordination bonds during poly-
merization (2, 3). The crucial role of the metal cofactor and
structurally conserved active site architecture in polymerases has
also been demonstrated by validating Mg2+ as a target for the
design of antiviral drugs, not only against HIV RT but also, among
others, against HIV integrase, HIV ribonuclease H (RNase H),
and influenza-encoded endonuclease (4, 5). Hence, it should be
feasible to design a universal but simplified (d)NTP mimic that
binds efficiently to a wide variety of DNA/RNA polymerases.
It was hypothesized that a universal nucleoside triphosphate
mimic should contain three major indispensable entities: (i) a
nucleobase part (i.e., to achieve optimal Watson–Crick base-
pairing with the template overhang), (ii) a replacement of the
triphosphate moiety that should enable efficient Mg2+-directed
coordination, and (iii) a variable linker between the nucleobase
and the modified triphosphate to mimic the pentose entity present
in natural (d)NTPs. For the triphosphate part, we chose an
α-carboxy phosphonate entity that is chemically stable in physio-
logical media and cannot be released from the triphosphate mimic
by cellular (hydrolytic) enzymes. It was assumed that the carboxyl-
ate in the phosphonate moiety might help to coordinate Mg2+.
The phosphonate moiety, such as in the clinically used tenofovir
(6), was chosen (instead of a phosphoester) to provide additional
metal chelation affinity and to confer stability by preventing
enzymatic hydrolysis. Given the fact that (2-deoxy)ribose, the
most logical linker entity between nucleobase and phosphonate,
could not be synthetically incorporated due to the intrinsic la-
bility of the ether oxygen bridge that links the pentose to the
phosphonate, a cyclopentyl ring was initially introduced as the
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linker moiety, as has been done before for the HIV-1 nucleoside
RT inhibitor (NRTI) carbovir (7).
To investigate and validate the design of a universal (d)NTP
mimic, we chose the well-characterized HIV-1 RT as a preferred
model system, as a variety of kinetic, biochemical, and structural
tools are available and well-established to study this enzyme.
Results
Kinetic Studies. The thymine (T)-, uracil (U)-, cytosine (C)-, and
adenine (A)-α-CNP (α-carboxy nucleoside phosphonate) deriv-
atives were synthesized and examined for their interaction with
HIV-1 RT. The α-CNPs were initially investigated not only as
their racemic dextrorotatory/levorotatory (D/L) (1:1) mixtures
but also as pure D- and L-enantiomers in the presence of three
different homopolymeric template/primers (i.e., poly rA.dT, poly
rI.dC, and poly rU.dA) and their corresponding [CH3-
3H]dTTP,
[5-3H]dCTP, and [2,8-3H]dATP substrates. Each of the α-CNP
enantiomers represents a pair of diastereomers at the alpha-
carboxy stereocenter. The D-enantiomers showed poor, if any,
inhibitory activity against HIV-1 RT, whereas the D/L-racemic
mixtures (8) and the pure L-enantiomers markedly inhibited
HIV-1 RT at concentrations (IC50, 0.19–4.3 μM) that were on
the same order of magnitude as the respective reference com-
pounds AZT-triphosphate (TP), ddCTP, and ddATP (IC50,
0.11–14 μM) (Table 1 and SI Appendix, Table S1). Pronounced
enzyme inhibition was found only when the α-CNPs contained
the same natural nucleobase as the competing radiolabeled dNTP
substrate. The template/primer-specific inhibition of HIV-1 RT
by α-CNPs strongly suggests that α-CNPs compete with the natural
dNTP substrate for binding to the enzyme. This conclusion was
further substantiated in more detailed kinetic experiments using
different homopolymeric template/primers and their correspond-
ing dNTP substrates, as evident from the substrate versus velocity
plots in SI Appendix, Fig. S2A and the kinetic calculations using
the mixed model inhibition of GraphPad (SI Appendix, Table S2).
These plots also revealed mixed-type (close-to-uncompetitive)
inhibition of RT against the template/primer by T-α-CNP
(SI Appendix, Fig. S2B), which indicates that binding of template/
primer to HIV-1 RT is required before efficient binding of the
α-CNP to the enzyme. Although structurally distinct, the α-CNP
inhibition kinetics (SI Appendix, Fig. S2 A and B) resembled not
only those of the well-known DNA chain-terminating NRTI
AZT-TP (SI Appendix, Fig. S2 C and D) (11) but also those of
the nucleotide-competing RT inhibitor (NcRTI) INDOPY-1
(SI Appendix, Fig. S2 E and F). INDOPY-1 is the prototype
compound of a well-defined class of nonnucleoside indolopyr-
idinones that interact—like NRTIs—with the substrate active
site of HIV RT in a competitive manner with the natural dNTP
substrates (12).
L-enantiomeric α-CNPs were also found to be inhibitory
against a broad variety of other lentiviral RTs (Table 1), mostly,
like nucleo(s)(t)ide RT inhibitors (N(t)RTIs), within the same
order of magnitude. Given the highly conserved structural motifs
(i.e., Asp/Glu residues) and functional coordination properties
of Mg2+ in the polymerase active sites, we hypothesized that
α-CNPs that function as (d)NTP mimics should also inhibit
other polymerases. The interactions of the T-, C-, and A-α-CNP
derivatives with several herpetic DNA polymerases were there-
fore investigated. As evident from Table 1, α-CNPs indeed in-
teract with the herpetic DNA polymerases and also, but less
strongly, with the cellular DNA polymerases α and β. The in-
hibitory activities of the triphosphate of the retroviral AZT
(zidovudine), the herpetic (E)-5-(2-bromovinyl)-2′-deoxyuridine
(BVDU, brivudine), and the pyrophosphate analog phosphono-
formic acid (PFA, foscarnet) inhibitors have been included as
controls (Table 1). AZT-TP proved 4- to 50-fold more inhibitory to
the lentiviral RTs, BVDU-TP was 10- to 100-fold more inhibitory to
the herpetic DNA polymerases, whereas PFA was equally inhibitory
against HIV-1 RT and FIV RT, 30-fold more inhibitory against
HIV-2 RT and SIV RT, four- to eightfold more inhibitory to
HCMV and HSV-1 DNA polymerase, and 200-fold more inhibitory
to VZV DNA polymerase than T-α-CNP. Instead, the reference
compounds BVDU-TP and PFA were markedly more inhibitory
against the cellular DNA polymerase α than the α-CNPs (Table 1).
Although the affinity of the α-CNPs was clearly superior for
HIV-1 RT, followed by herpetic DNA polymerases, and lowest
for the cellular DNA polymerases, it should be taken into account
that the pentose mimicking (cyclopentyl) part of the α-CNP is
more suited to inhibit RTs (mimicking a 2′,3′-dideoxyribose) and
least appropriate for inhibiting the cellular DNA polymerases α
and β, which prefer an intact 2-deoxyribose. Taking this in mind,
an acyclic α-CNP has been designed (SI Appendix, Fig. S3) con-
taining an aliphatic butenyl bridge. Such an aliphatic (acyclic)
moiety has previously been shown to generate compounds with
antiherpetic activity (13). This modified α-CNP indeed demon-
strated a pronounced inhibition of all three herpetic DNA poly-
merases, and its inhibitory activity was by far superior (selective) for
these viral enzymes compared with HIV RT and DNA polymerase
Table 1. Inhibitory activity of the L-enantiomeric α-CNPs against various lentiviral RTs and
other DNA polymerases*
IC50
† DNA polymerase, μM
Enzyme source T-α-CNP C-α-CNP A-α-CNP BVDU-TP AZT-TP PFA
HIV-1 RT 0.41 ± 0.08 4.3 ± 0.3 0.19 ± 0.11 0.89 ± 0.04 0.11 ± 0.05 0.34 ± 0.01
HIV-2 RT 4.4 ± 1.9 22 ± 4.9 0.43 ± 0.05 2.6 ± 1.2 0.08 ± 0.03 0.16 ± 0.09
SIV RT 1.3 ± 0.6 20 ± 11 0.43 ± 0.00 4.6 ± 2.1 0.09 ± 0.01 0.05 ± 0.01
FIV RT 0.49 ± 0.05 11 ± 8 2.1 ± 0.8 2.6 ± 0.6 0.07 ± 0.02 0.59 ± 0.07
Visna RT 4.1 ± 1.1 46 ± 6 0.16 ± 0.06 — 0.09 ± 0.01 —
HCMV DNA polymerase 38 ± 11 17 ± 11 23 ± 6.7 3.6 ± 0.7 >100 9.8 ± 5.8
HSV-1 DNA polymerase 26 ± 20 19 ± 2 3.5 ± 1.1 0.75‡ — 3§
VZV DNA polymerase 38 ± 16 — — 0.49 ± 0.09 5.7 ± 3.2 0.18 ± 0.01
DNA polymerase α 229 ± 27 269 ± 89 171 ± 21 21 ± 10 >100 7.7 ± 6.5
DNA polymerase β >200 ≥200 >200 26 ± 4 ≥200 >200
*Each α-CNP represents a pair of diastereomers at the alpha-carboxy stereocenter.
†Fifty percent inhibitory concentration required to inhibit polymerase activity by 50%. Shown are mean ± SD
values of at least 2–4 independent experiments.
‡IC50 value was taken from ref. 9. The IC50s of BVDU-TP for cellular DNA pol α and β were 9.2 and 47 μM,
respectively, using similar assay conditions.
§IC50 value was taken from ref. 10.
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α (Table 2). Thus, marked selectivity and preferential interaction
with well-defined polymerases can be obtained by fine-tuning the
α-CNP scaffold to the particular target (polymerase) enzymes.
Biochemical Studies. To provide more detailed mechanistic in-
sight, inhibition of DNA synthesis was studied in gel-based
assays. Dose–response experiments were performed with hetero-
polymeric DNA/DNA substrates that offer multiple binding sites
for inhibitor and natural substrates (Fig. 1A and SI Appendix,
Fig. S4). T-, C-, or A-containing α-CNPs (pure L-enantiomers)
show inhibition patterns that reflect the different nature of the
nucleobase. Inhibition of DNA synthesis is always observed at
a single site before the predicted location at which the compet-
itive inhibitor interacts with its natural template nucleobase
counterpart (Fig. 1A). This also demonstrates that α-CNPs are
not incorporated into the growing DNA chain, which would have
changed the primer migration. Time-course experiments at a
fixed concentration of α-CNPs revealed that inhibition is rever-
sible (SI Appendix, Fig. S4). In the presence of the respective T-,
C-, or A-containing α-CNPs, the formation of the full-length
product was significantly delayed, in favor of multiple abortive
products. The short reaction products disappeared as a function
of time, which is indicative of enzyme pausing and reversible
inhibition. Hence, the mechanism of α-CNP inhibition does not
involve DNA chain termination as demonstrated for N(t)RTIs
(7, 11). Rather, the RT inhibition by α-CNPs is reminiscent of
the mechanism of action described for INDOPY-1 (12) and
involves reversible competition at or in close proximity to the
dNTP-binding site.
Next, it was investigated if α-CNPs are capable of forming
stable ternary complexes, as demonstrated for nucleotides and
INDOPY-1. Complex formation was monitored with increasing
concentrations of C-α-CNP against four different template/primer
combinations that contained either T, A, G, or C in the template
overhang at the nucleotide-binding site (Fig. 1B). Stable, hepa-
rin-resistant ternary complexes were only seen with a templating
guanine base, which is strongly indicative for specific Watson–
Crick base-pairing. These findings contrast with the NcRTI
INDOPY-1, which was able to form a stable ternary complex
irrespective of the nature of the templating nucleotide base (SI
Appendix, Fig. S5).
Finally, the influence of the inhibitor on the precise position
of HIV-1 RT on its template/primer was studied through Fe2+-
mediated, high-resolution footprinting. Upon binding of Fe2+
ions to the RNase H domain of HIV-1 RT, the template is cut
in a site-specific manner that enables the distinction between
pre- and posttranslocational conformations of the RT–template/
primer complex (14). The enzyme shuttles between the two posi-
tions and accommodates either the 3′ end of the primer (pre-
translocation) or the nucleotide substrate (posttranslocation) at the
active site. Increasing concentrations of C-α-CNP shift this dynamic
equilibrium toward posttranslocation (SI Appendix, Fig. S6). Thus,
α-CNPs, like natural dNTP substrates and like INDOPY-1 (12),
bind to, and trap, the posttranslocational RT conformation.
Structural Studies. The crystal structure of the HIV-1 RT/dsDNA/
T-α-CNP ternary complex was determined at 2.9 Å resolution
(Fig. 2A and SI Appendix, Fig. S7 and Table S3). In agreement
with the kinetic data, the structure revealed the binding of T-α-
CNP at the dNTP-binding site (N site) of an RT/dsDNA post-
translocational complex. Mimicking a dNTP, (i) the thymine part
of T-α-CNP is base-paired with the template adenine base over-
hang; (ii) the cyclopentyl ring interacts with Y115, Q151, and
M184 from three sides in a manner analogous to the interactions
of the 2′-deoxyribose ring of a dNTP; and (iii) the carboxymethyl-
phosphonate part chelates a Mg2+ ion (metal B) at the polymerase
active site. In general, binding of T-α-CNP is analogous to a dNTP
and distinct from a pyrophosphate (or foscarnet), which binds the
pretranslocated RT/nucleic acid complex at a location that can be
occupied by the pyrophosphate (PPi) leaving group (15).
The most striking feature is the unusual and unexpected mode
of chelation of the α-carboxy-phosphonate at the polymerase
active site. Two oxygens of the phosphonate group of α-CNP
chelate metal B, replacing the chelation by β- and γ-phosphate
oxygens of a dNTP. A carboxyl oxygen of α-CNP is the positional
equivalent of the α-phosphate oxygen of dNTP that chelates both
metals A and B. The positions and orientations of the catalytic
residues (D110, D185, and D186) in the T-α-CNP complex su-
perimpose well with those in RT/nucleic acid/dNTP (or analog)
ternary complexes (SI Appendix, Fig. S7). However, like in most
of the crystal structures of RT/dsDNA/dNTP (or analog) com-
plexes (16), electron density for metal A is not observed. Thereby,
the α-CNP in the current structure maintains a complete octa-
hedral coordination environment for the catalytic metal ion B and
satisfies the geometrical and chemical requirements to involve the
metal ion A (Fig. 2B). Unlike a triphosphate moiety, the chelated
α-carboxy-phosphonate group does not contain a phosphodiester
bond for hydrolysis by RT, and thereby, α-CNP forms a non-
productive ternary complex state with RT, leading to inhibition.
This fundamental and indispensable role of the Mg2+-coordinating
capacity of the three oxygens in the α-CNP is further confirmed by
the demonstration that modifying one of these three oxygen atoms
in the α-CNP with a methyl group such as in the mono- and tri-
methylated T-α-CNP (SI Appendix, Figs. S3 and S7) completely
obliterated the interaction of the compounds with HIV RT (IC50 >
100 μM). Thus, α-CNPs are entirely novel, efficient, and simplified
mimics of the natural dNTP substrates that inhibit HIV-1 RT as
competitive inhibitors.
Sensitivity Against HIV-1 RT with Known Resistance-Conferring
Mutations. Like NRTIs, α-CNPs are sensitive to RT mutations
adjacent to the pentose/cyclopentyl ring. The mutation M184V
confers 1.7- to 16-fold resistance to α-CNPs depending on the
nature of the nucleobase in the α-CNP (SI Appendix, Table S4).
The M184V mutation has also been reported to confer re-
sistance of HIV-1 RT to INDOPY-1 (17), and earlier also to the
L-nucleoside inhibitors lamivudine (3TC) and emtricitabine
(FTC) (18). This resistance was shown to be due to steric hin-
drance of the L-sugar ring by the 184-valine side chain (19). The
crystal structure suggests a similar mechanism of resistance for
α-CNPs by the M184V mutation in HIV-1 RT. Another mutation,
Table 2. Inhibitory activity of acyclic T-butenyl-α-CNP and T-cyclopentyl-α-CNP against various
DNA polymerases
IC50* DNA polymerase, μM
HIV-1 RT HCMV DNA pol HSV-1 DNA pol VZV DNA pol DNA pol α
Acyclic T-butenyl-α-CNP 235 ± 16 2.1 ± 0.6 3.7 ± 1.7 2.2 ± 0.1 14 ± 7
T-α-CNP 0.41 ± 0.10 38 ± 11 26 ± 20 38 ± 16 229 ± 27
*Fifty percent inhibitory concentration required to inhibit enzyme activity by 50%. Mean ± SD values of at least
2–3 independent experiments are shown.
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Y115F, demonstrated diminished inhibitory activity of the NcRTI
INDOPY-1 against HIV-1 RT (17), however the mutation had no
noticeable impact on the inhibitory activity of the C- and A-α-CNPs
(SI Appendix, Table S4). The decreased inhibitory activity of
INDOPY-1 against mutant Y115F HIV-1 RT has been earlier as-
cribed to the increased binding efficiency of the natural dNTP (but
not INDOPY-1) to the mutant enzyme (16). These findings strongly
suggest that the affinity of RT for α-CNPs is similarly increased in
the mutant RT enzyme as observed for the dNTPs. The sensitivity
data obtained for the Y115F and M184V RT mutants confirm
again that α-CNPs act as novel dNTP mimics in the substrate active
site of HIV-1 RT that is lined by both Y115 and M184.
Interference of α-CNPs with dNTP-Driven Enzyme Regulation. For
a wide variety of enzymes, the activity is controlled by their
reaction products or metabolic end-products through feedback
or allosteric regulation. Well-known examples in nucleotide
metabolism are inhibition of cytosolic thymidine (dThd) kinase 1
(TK-1) and mitochondrial TK-2 by Mg2+-dTTP; TK-2 and dCyd
kinase inhibition by Mg2+-dCTP; dCMP deaminase (dCMPD)
stimulation by Mg2+-dCTP; ribonucleotide reductase regulation
by Mg2+-bound dNTP and ATP; and allosteric activation of
dNTP hydrolase by (d)GTP (20–24). Therefore, the potential of
α-CNPs to act as dNTP mimics in such enzymatic regulation
processes was also investigated.
Fig. 1. Inhibition of HIV-1 RT-catalyzed DNA synthesis by α-CNPs. (A) Inhibition of DNA synthesis monitored in dose–response experiments in the presence of
a fixed dNTP concentration, T50A DNA template/5′-radiolabeled P1 DNA primer, and increasing concentrations of T-, C-, and A-α-CNP, respectively (right
block). Specific sites of inhibition by each of the three compounds are located a single residue before the inhibitor- and dNTP-binding sites. The left block
shows control reactions with the obligate DNA chain-terminating ddNTPs. (B) Ternary RT template/primer inhibitor complex formation. Specific α-CNP binding
to HIV-1 RT was analyzed with four different template/primer combinations that contain either a T-, A-, G-, or C-nucleotide, downstream of the 3′-primer end.
Complex formation with HIV-1 RT was monitored with increasing C-α-CNP concentrations.
Fig. 2. Molecular interactions of T-α-CNP with HIV-1
RT. (A) A stereoview showing the binding of T-α-CNP
at the polymerase active site in the crystal structure
of HIV-1 RT in complex with a template/primer and
T-α-CNP. The template overhang was designed to
have an adenine base overhang for base-pairing
with T-α-CNP. The 2.9 Å difference electron density
(jFoj – jFcj) map contoured at 3 σ reveals the binding
of T-α-CNP. Interacting residues of RT surrounding
T-α-CNP are in cyan. The metal ion B has distorted
octahedral coordination involving three oxygens of
T-α-CNP, side chains of catalytic aspartates D110 and
D185, and main chain C = O of V111. (B) A schematic
comparison of the structural interactions of T-α-CNP
(Left) and the natural dTTP (Right) with HIV-1 RT and
the template/primer. The interactions shown are, in
part, derived from the crystal structure coordinates
as displayed in A. Because metal ion A was not ob-
served in the crystal structure, the presumed in-
teraction of metal ion A with D186, the 3′-OH end of
the primer, and the oxygens of D110, D185, and the
α-COOH of T-α-CNP is shown in the Left panel, by
analogy with what has been demonstrated before
for dNTPs (i.e., dTTP). The octahedral coordination of
Mg2+ (metal ion B) reveals the participation of the
carboxylate oxygen mimicking the interaction of the
α-phosphate with Mg2+ and the participation of two
phosphonate oxygens mimicking the interaction of
the β- and γ-phosphates with Mg2+. A structural su-
perposition in SI Appendix, Fig. S7 compares the
binding of T-α-CNP with a dNTP.
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Interestingly, T-α-CNP, but not C- and A-α-CNPs, dose-
dependently inhibited TK-2–catalyzed dThd phosphorylation (Fig. 3).
The natural metabolic end-product inhibitor Mg2+-dTTP suppressed
the enzyme at a ∼20-fold lower concentration (IC50, ∼2.5 μM). The
herpesvirus TKs were less sensitive to the inhibitory action of
dTTP and α-CNPs. In contrast with TK-2, TK-1 was not in-
hibited by T-α-CNP (IC50, >200 μM), although Mg2+-dTTP
showed a pronounced feedback inhibition of the enzyme (IC50,
1.5 μM) (Fig. 3 and SI Appendix, Fig. S8). T-α-CNP behaved as
a noncompetitive inhibitor of TK-2 in the presence of dThd and
thus might interact at a regulatory binding site (SI Appendix, Fig.
S8 and Table S5) (25). Our kinetic findings are indeed strongly
suggestive for specific recognition of T-α-CNP by TK-2. The
complete lack of inhibitory activity of T-α-CNP against TK-1 may
be related to the fact that TK-1 belongs to the type I class of TKs
and structurally differs from type II class TK-2 and herpetic TKs
(26). It has been demonstrated that the nucleobase of the natural
allosteric TK inhibitor dTTP is hydrogen-bonded to main-chain
atoms in TK-1, in contrast to other nucleoside kinases where
specific interaction occurs with amino acid side chains (26).
The C-α-CNP derivative was found to interact with the stim-
ulatory allosteric Mg2+-dCTP binding site on dCMPD. In the
absence of dCTP, dCMPD activity could be hardly observed.
Instead, in the presence of 250 μM dCTP, a pronounced de-
amination of dCMP was found that linearly proceeded up to
a dCMP concentration of 100 μM (SI Appendix, Fig. S8). Unlike
dCTP, C-α-CNP did not stimulate dCMPD activity per se but
instead markedly inhibited the Mg2+-dCTP–driven enzyme activity
(SI Appendix, Fig. S8). It was also ascertained that C-α-CNP did
not act as a substrate for dCMPD. The dose-dependent inhibition
profiles of C-α-CNP against dCMPD in the presence of a fixed
dCTP (250 μM) concentration were remarkably similar at varying
dCMP concentrations. Thus, our findings indicate that C-α-CNP
selectively interacts with the allosteric stimulatory (Mg2+-dCTP)
binding site of dCMPD by antagonizing the dCTP stimulatory
effect without being able to stimulate enzyme activity per se.
The interference of α-CNPs with allosteric inhibitory or stimu-
latory activities of (d)NTP-binding proteins may have therapeutic
potential, as it has been previously demonstrated that dCTP not
only stimulates the conversion of dCMP into dUMP (21) but also
the conversion of the anticancer cytosar (araCMP) and gemcita-
bine (dFdCMP) metabolites to their inactive uridylate derivatives
(27, 28). α-CNP may prevent such inactivation by its antago-
nistic potential.
Studies on Intact Cells, Crude Cell Extracts, and Purified Enzymes. The
T-α-CNP, C-α-CNP, and A-α-CNP derivatives were exposed to
exponentially growing human CD4+ T lymphocyte CEM and
cervix carcinoma HeLa cell cultures but also confluent (mono-
layer) human lung fibroblast HEL and HeLa cell cultures for
3–4 d. None of the compounds were cytostatic or cytotoxic at
200 μM. They were also evaluated for potential anti–HIV-1 and
anti–HIV-2 activity in human CD4+ T-lymphocyte CEM cell
cultures and for anti–HSV-1 and anti–HSV-2 activity in human
embryonic lung HEL fibroblasts, but found inactive at the highest
concentration tested (200 μM).
To reveal whether cellular enzymes may further metabolize
(i.e., phosphorylate) the α-CNPs, CEM cell extracts but also purified
recombinant UMP/CMP kinase and NDP kinase were administered
to 100 μM T-α-CNP, U-α-CNP, C-α-CNP, or A-α-CNP in the
presence of ATP and incubated for up to 6 h at 37 °C. They were
not able to convert the compounds to a phosphorylated derivative,
as inspected by HPLC analysis. Instead, 100 μM CMP or UMP
was fully converted to cytidine diphosphate (CDP) or UDP by
UMP/CMP kinase, and 100 μM thymidine diphosphate (dTDP),
CDP, or adenosine diphosphate (ADP) was efficiently converted
to their triphosphate derivatives by NDP kinase within 1 h of
incubation.
Discussion
Kinetic, biochemical, and structural studies revealed that α-CNPs
represent a novel synthetic scaffold and technological platform
for designing specific tailor-made polymerase inhibitors that
make use of both the highly conserved architecture and amino
acid motifs in nucleic acid polymerases and the central role that
hexa-coordinated Mg2+ plays in the catalytic activity of the poly-
merases. The α-CNPs function as efficient (d)NTP mimics in
which one of the carboxylate oxygens and two phosphonate
oxygens are of crucial importance in coordinating Mg2+ ions.
The α-CNPs are the first (d)NTP mimics that structurally consist
of a simple nucleoside monophosphonate scaffold not requiring
further metabolic conversion (phosphorylation) for interaction
with the target enzymes. Their mechanism of action, structural
interaction with HIV-1 RT, and kinetic/biochemical properties
are unique and differ from all known polymerase inhibitor classes
of compounds (SI Appendix, Table S6).
The demonstration that α-CNPs inhibit different polymerases
and enzymes that contain regulatory dNTP-binding sites is
unique from a fundamental viewpoint and may also have im-
portant translational and chemotherapeutic implications. The
α-CNPs can be used to study allosteric (dNTP) site binding
effects leading to selective antagonistic inhibition or activation of
enzyme activity. It has indeed been shown earlier that thymidine
kinase activity can be modulated by 5′-amino-dThd (5′-AdThd),
as the natural dTTP does, affecting the cytotoxicity and metab-
olism of various dThd analogs used in the clinic as antineoplastic
agents (29). 5′-AdThd was shown to antagonize dTTP feedback
inhibition of TK and therefore to stimulate the anabolism of the
anticancer drug 5-FdUrd (30). Thus, the use of compounds ca-
pable of antagonizing feedback inhibition of nucleoside analog
activation (phosphorylation) may provide new means of increasing
the efficacy of cytotoxic (anticancer) nucleoside analogs.
The α-CNPs might also have the intrinsic ability to target a
wide variety of other (d)NTP-binding proteins, potentially also
including G protein-coupled receptors (31), providing new op-
portunities in drug discovery. G protein-coupled receptors include
a most diverse group of membrane receptors responsible for con-
ducting many physiological processes through signal transduction,
including intercellular communication, neuronal transmission, and
hormonal signaling (32). They are also involved in a variety of
pathological processes (31, 33) and are currently targets for at least
one third of the pharmaceutical drug market (31).
Fig. 3. Allosteric inhibition of TK by T-α-CNP and dTTP. Exposure of the L-
enantiomeric T-, C-, and A-α-CNPs to cytosolic TK-1, mitochondrial TK-2, HSV-1
TK, and varicella-zoster virus TK at varying α-CNP concentrations (Upper
panels). The natural feedback regulatory inhibitor dTTP was included as
a positive control (Lower panels). Whereas Mg2+-dTTP potently inhibited
TK-1, TK-2, and VZV TK, T-α-CNP markedly suppressed TK-2 and VZV TK ac-
tivity but not TK-1.
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The design of α-CNPs may also represent a technological tool
for facilitating biochemical and structural studies of (d)NTP-
binding proteins in the presence of α-CNPs as nonhydrolysable
(d)NTP mimics. In fact, the nonhydrolysable ATP mimic aden-
osine 5′-(β,γ-methylene)triphosphate has been demonstrated to
be instrumental for an improved crystallography of proteins that
use ATP as one of their ligands and to obtain mechanistic
insights in the role of ATP in enzyme interaction and catalysis
(34, 35). Therefore, α-CNPs should be further investigated for
their interaction with (d)ATP-, (d)CTP-, or (d)TTP-binding pro-
teins from a crystallographic and mechanistic viewpoint.
None of the α-CNPs have shown so far any significant cyto-
static or cytotoxic activity in cell culture at concentrations as
high as 100 μM. However, one of the reasons may be the poor,
if any, efficient cellular uptake of the α-CNPs due to their
highly charged nature. Cellular uptake should therefore be
enhanced by designing lipophilic prodrugs of the α-CNPs neu-
tralizing the phosphonate charge, a strategy that is applied in
the clinically used drugs adefovir dipivoxil (Hepsera), tenofovir
disoproxil (Viread), and tenofovir alafenamide (36, 37). These
attempts are currently ongoing in our laboratories. Although it
should be recognized that α-CNP selectivity will be a challenge
in terms of target specificity, structural optimization (fine-
tuning) in the nucleobase, α-carboxy phosphonate, and/or the
linker (pentose) portions of the molecules may address this
issue, as already demonstrated for the acyclic α-CNPs that are
shown to have a shifted selectivity from HIV-1 RT to herpetic
DNA polymerases.
Methods
Detailed descriptions of the experimental set-ups and compound charac-
terization are provided in SI Appendix, SI Methods. Inhibition of RTs by the
α-CNPs was evaluated using the respective homopolymeric template/primers
poly rA.dT, poly rI.dC, and poly rU.dA and their appropriate corresponding
radiolabeled dNTP substrates (Table 1) or in the presence of T50A DNA
template/5′-radiolabeled PI DNA primer and a fixed dNTP concentration (Fig.
1). The herpetic DNA polymerases and the cellular DNA polymerases used
gapped calf thymus DNA as the template (Table 1), except for VZV DNA
polymerase, where poly dA.poly dT was used. The X-ray diffraction data
were obtained for the HIV-1 RT/dsDNA/T-α-CNP ternary complex that
contained a template adenine base overhang to allow base-pairing with
T-α-CNP (Fig. 2). Allosteric inhibition of viral and cellular thymidine kinases
and cellular dCMPD by α-CNPs was performed in the presence of the natural
substrates (dThd and dCMP, respectively) and dCTP (for the dCMPD assay) and
analyzed by anion exchange HPLC (Fig. 3).
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ONLINE METHODS 
Reverse transcriptase, nucleic acids, and small molecules 
HIV-1 reverse transcriptase was expressed and purified as described previously (1). 
Oligodeoxynucleotides were synthesized and purchased from Integrated DNA Technologies, 
Coralville, USA. The following sequences were used as templates: T50A, 
CCAATATTCACCATCAAGGCTTGACGTGACTTCACTCCACTATACCACTC; PBS36a, GTAACT- 
AGATATCCCTCAGACCCTTTTAGTCAGAAT; PBS36t, GTAACTAGAAATCCCTCAGACCCTTT- 
TAGTCAGAAT, PBS36c, GTAACTAGAGATCCCTCAGACCCTTTTAGTCAGAAT; PBS36g, 
GTAACTAGACATCCCTCAGACCCTTTTAGTCAGAAT; PPT57, CGTTGGGAGTGAATTAGCC-
CTTCCAGTCCCCCCTTTTCTTTTAAAAAGTGGCTAAGA. Primer sequences used were: P1, 
GAGTGGTATAGTGGAGTGAA; 8a, TTCTGACTAAAAGGGTCTGAGGGAT; PPT+16, 
AAAGGGGGGACTGGAAGGGCTAATT. Deoxynucleotides were purchased from Integrated DNA 
Technologies. 
Compound characterization data 
T-α-CNP [cis-1-{4-[Carboxy(phosphono)methoxy]cyclopentan-1-yl}thymine] 
White solid; mp 228–230 °C; νmax/cm−1 (KBr) 3152 (NH), 3025 (CH), 1691 (C=O), 1405, 1273 (P=O), 
1058; 1H NMR (600 MHz, D2O) δ: 1.53–1.62 (m, 0.5H), 1.62–1.75 (m, 2.5H), 1.76 (s, 3H), 1.80–1.98 
(m, 2H), 2.24–2.31 (m, 1H), 3.92 (d, PCH, JPH = 18.6, 0.5H), 3.95–4.02 (m, 1.5H), 4.73–4.84 (m, 1H), 
7.70 (s, 0.5H), 7.72 (s, 0.5H); 13C NMR (150.9 MHz, D2O) δ: 11.4, 11.5, 29.1, 29.2, 29.5, 30.6, 36.6, 
37.5, 54.6, 54.8, 77.5 (d, JPC = 143.5), 78.2 (d, JPC = 143.4), 79.9 (d, JPC = 11.2), 80.6 (d, JPC = 10.9), 
111.3, 111.4, 140.3, 140.5, 152.57, 152.59, 166.6, 176.3, 176.5; 31P NMR (121.5 MHz, CDCl3) δ: 12.4, 
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12.6; HRMS (ES+): calcd for C12H18N2O8P (M + H)+ 349.0801, found 349.0804; MS (ES+) m/z: 349 (M + 
H)+. 
C- α-CNP [cis-1-{4-[Carboxy(phosphono)methoxy]cyclopentan-1-yl}cytosine] 
White solid; mp > 250 °C; υmax/cm−1 (KBr): 3432 (br, NH), 2966 (CH), 1723 (C=O), 1650, 1595 (C=C), 
1490, 1399, 1286 (P=O), 1172 (C-N), 1087 (C-O); 1H NMR (600 MHz, D2O) δ: 1.52–1.60 (m, 0.5H), 
1.60–1.72 (m, 2.5H), 1.81–1.92 (m, 1H), 1.93–2.01 (m, 1H), 2.19–2.31 (m, 1H), 3.88 (d, JPH = 18.0, 
0.5H), 3.91–3.95 (m, 0.5H), 3.92 (d, JPH = 18.6, 0.5H), 3.96–4.00 (m, 0.5H), 4.82–4.90 (m, 1H), 5.915 
(d, J = 7.2, 0.5H), 5.923 (d, J = 7.8, 0.5H), 7.96 (d, J = 7.2, 0.5H), 7.97 (d, J = 7.2, 0.5H); 13C NMR (150 
MHz, D2O) δ: 29.4, 30.0, 30.3, 31.1, 36.6, 37.9, 55.3, 55.6, 77.7 (d, JPC = 142.1,), 78.4 (d, JPC = 141.4, 
79.8 (d, JPC = 11.5), 80.5 (d, JPC = 11.8), 96.30, 96.34, 144.7, 144.8, 158.42, 158.45, 165.35, 165.37, 
176.8, 177.1; 31P NMR (121.5 MHz, D2O) δ: 11.3, 11.5; HRMS (ES+): calcd for C11H17N3O7P (M + H)+ 
334.0804, found: 334.0802; MS (ES–) m/z: 332.0 (M – H)−. 
A- α-CNP [cis-9-{4-[Carboxy(phosphono)methoxy]cyclopentan-1-yl}adenine] 
White solid; mp 236–240 °C; νmax/cm−1 (KBr) 3342 (NH), 3198, 2961 (CH), 1603 (C=O), 1396, 1176 (C-
N), 1071 (C-O); 1H NMR (600 MHz, D2O) δ: 1.86–2.23 (m, 5H), 2.55–2.64 (m, 1H), 3.91 (d, JPH = 16.8, 
0.55H), 3.96 (d, JPC = 16.8, 0.45H), 4.09–4.17 (m, 1H), 4.75–4.83 (m [partially obscured by water], 1H), 
8.11 (s, 0.45H,), 8.12 (s, 0.55H), 8.45 (s, 0.45H), 8.50 (s, 0.55H); 13C NMR (150 MHz, D2O) δ: 29.3, 30.5, 
30.6, 30.7, 37.5, 38.6, 53.6, 53.8, 77.4 (d, JPC = 145.9), 78.1 (d, JPC = 148.8), 79.9 (d, JPC = 10.3), 80.5 (d, 
JPC = 10.7), 117.8, 117.9, 141.11, 141.14, 148.2, 151.2, 154.5, 154.6, 176.6, 176.8; 31P NMR (121.5 
MHz, D2O) δ: 11.7, 11.8; HRMS (ES+): calcd for C12H17N5O6P (M + H)+ 358.0916, found 358.0898; MS 
(ES–) m/z: (M – H)– 
Acyclic T-butenyl- α-CNP [cis-2-(4-(2,4-Dioxo-5-methyl-pyrimidin-1-yl)but-2-enyloxy)-2-
phosphonoacetic acid] 
White solid; δH (300 MHz, D2O): 1.78 (s, 3H), 3.84-3.90 (d, 1H, JPH= 18.6 Hz), 4.02-4.19 (m, 2H), 4.35-
4.37 (m, 2H), 5.49-5.58 (m, 1H), 5.79-5.82 (m, 1H), 7.41 (s, 1H) ppm; δC (75 MHz, D2O): 11.2, 45.4, 
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66.3, 66.5, 79.8, 81.6, 110.9, 126.5, 130.7, 142.8, 152.3, 167.1, 177.4 ppm; δP (160 MHz, CDCl3): 12.3-
12.4 (d, J= 17 Hz) ppm; LRMS (ESI) mass calculated for C11H15N2O8P (M+H)+ 335.1; Found: 335.4. 
DNA synthesis 
A 3-fold excess of T50A DNA template was heat-annealed to 50 nM 5'-radiolabeled P1 DNA primer, 
then incubated with 250 nM of RT in a buffer containing 50 mM Tris-HCl pH 7.8, 50 mM NaCl, 0.3 mM 
EDTA, and 0.5 µM of each of dATP, dTTP, dGTP, and dCTP (1). The samples were preincubated at 37°C 
for 5 minutes before starting the reactions. In the time course experiment, samples were treated 
with either no inhibitor, or 200 µM of T-α-CNP, C-α-CNP, or A-α-CNP; the reactions were initiated 
with 6 mM MgCl2 and allowed to proceed for up to 30 minutes. For inhibitor dose-response 
experiments, each of the three inhibitors was titrated up to 200 µM, and the reaction was initiated 
with 6 mM MgCl2 and allowed to proceed for 3 minutes. For both types of experiments, the reaction 
was stopped with 100% formamide loading dye containing traces of xylene cyanol and bromophenol 
blue. Samples were resolved on a 12% denaturing polyacrylamide gel followed by phosphorimaging 
(Amersham Biosciences). For the dose-response experiments, pausing sites caused by inhibition were 
quantified and summed; the % inhibition was calculated as the total amount of inhibited product 
divided by the amount of full-length product plus inhibition products, multiplied by 100. The product 
fractions were normalized and plotted against inhibitor concentration using GraphPad Prism 
software; the normalized data was fitted to a log[inhibitor] versus response curve with variable slope 
to extract IC50 values for the inhibition of WT and mutant RT enzymes by the α-CNP. 
Electrophoretic mobility shift assay (EMSA) 
Ternary complex formation was monitored using 50 nM of a 5’ radiolabeled primer (8a) annealed to a 
three-fold molar excess of one of four templates (PBS36/a/t/c/g). The DNA hybrid was incubated 
with 500 nM WT HIV-1 RT in a buffer containing 50 mM Tris-HCl pH 7.8 and 6 mM MgCl2 in a final 
volume of 25 µL. Serial dilutions of C-α-CNP were added to the sample set and the tubes were 
incubated for 10 min at 25°C. Challenge of complexes was performed by addition of 4 µg/µl heparin, 
and subsequent incubation for 30 minutes at 25°C. Five µL of a solution containing 50% sucrose and a 
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trace of bromophenol blue was then added to the samples. Complexes were subjected to 6% non-
denaturing polyacrylamide electrophoresis and analyzed by phosphorimaging. 
Site-specific footprinting 
Chemical footprinting with Fe2+ of the template strand was conducted using 50 nM 5'-radiolabeled 
DNA template (PPT-57) annealed to 150 nM of the primer (PPT+16). The hybrid was incubated with 
750 nM HIV-1 RT in a buffer containing 120 mM sodium cacodylate (pH 7), 20 mM NaCl, and 6 mM 
MgCl2 in a final volume of 50 μL. Increasing concentrations of C-α-CNP were added to the samples; 
control lanes using the prototype translocational inhibitors PFA (PRE) and INDOPY-1 (POST) were 
included, in addition to samples without inhibitor and without Fe2+ treatment. Pre-incubation of 
complexes at 37°C for 10 minutes was performed prior to the treatment with Fe2+.  Treatment with 
Fe2+ was performed as previously described (2). 
Reverse transcriptase assay with homopolymeric template/primers 
HIV-I RT assays were also carried out in the presence of artificial homopolymeric template/primers. 
Poly(A), dT12-18, dC12-18, poly(I), dA12-18 and poly(U) were from Pharmacia (Uppsala, Sweden). To 
prepare the template/primers for the RT experiments, 0.15 mM poly(U), poly(A), and poly(I) were 
mixed with an equal volume of 0.0375 mM oligo(dA), oligo(dT), and oligo(dC), respectively. The 
reaction mixture (50 µl) contained 50 mM Tris.HC1 pH 7.8, 5 mM dithiothreitol, 300 mM glutathione, 
500 µM EDTA, 150 mM KCl, 5 mM MgCl2, 1.25 µg of bovine serum albumin, an appropriate 
concentration of the tritium-labeled substrate [CH3-3H]dTTP, [5-3H]dCTP, or [2,8-3H]dATP (2 
µCi/assay), a fixed concentration of the template/primer poly(A).oligo(dT) (0.015 mM), 
poly(I).oligo(dC) (0.015 mM), or poly(U).oligo(dA) (0.015 mM), 0.06% Triton X-100, 10 µl of α-CNP 
inhibitor solution (containing various concentrations of the compounds), and 1 µl of the HIV-1 RT 
preparation. The reaction mixtures were incubated at 37°C for 30 minutes, at which time 100 µl of 
calf thymus DNA (150 µg/ml), 2 ml of Na4P207 (0.1 M in 1 M HCl), and 2 ml of trichloroacetic acid (10% 
v/v) were added. The solutions were kept on ice for 30 minutes, after which the acid-insoluble 
material was washed and analyzed for radioactivity. For the experiments in which the 50% inhibitory 
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concentration (IC50) of the test compounds was determined, fixed concentrations of 1.25 µM 
[3H]dTTP, 1.75µM [3H]dATP, or 2.5 µM [3H]dCTP were used. In the assays in which the IC50 and Ki 
values of the test compounds were determined with respect to the template/primers, appropriate 
concentrations of template/primer were used. For the experiments in which the Ki values of the test 
compounds were determined with respect to the template/primers, appropriate concentrations of 
the template/primers were used in the presence of a fixed concentration of 1.25 µM [3H]dTTP, 1.75 
µM [3H]dATP, and 2.5 µM [3H]dCTP.  
Enzyme assay with HCMV DNA polymerase 
The pGEM3Z-CMV UL54 plasmid for expression of the catalytic subunit (UL54 protein) of HCMV DNA 
polymerase was a generous gift from T. Cihlar (Gilead Sciences, Foster City, CA) (3). Protein 
expression was performed with the TnT® SP6 Quick Coupled Transcription/Translation System 
(Promega) (4). The plasmid was added (at 10 ng per µl volume) to the TnT® mix containing 0.5 mM 
MgCl2 and 10 mM potassium acetate, and the mixture was incubated for 3 hours at 30°C. To perform 
the HCMV DNA polymerase assay, 4 µl of the TnT® reaction product was added to a 46 µl mixture to 
obtain 25 mM Tris.HCl pH 8.0, 100 mM (NH4)2SO4, 0.5 mM dithiothreitol, 10 mM MgCl2, 0.2 mg/ml 
bovine serum albumin, 5 % glycerol, 150 ng per µl activated calf thymus DNA (from Amersham 
Biosciences, Piscataway, N.J.), 100 µM of each of the three unlabeled dNTPs, and 0.5 µM of the rate-
limiting tritium-labeled dNTP, and serial dilutions of the L-enantiomeric α-CNPs. Foscarnet was 
included as the reference compound. After 60 minutes incubation at 37°C, nucleic acids were 
precipitated by addition of 1 ml of ice-cold 5% TCA and 20 mM Na4P2O7, then spotted onto glass 
microfiber filters (type G/C; GE Health Care UK Limited, Buckinghamshire, UK) and further washed 
with 5% TCA and ethanol to remove free radiolabeled dNTP. Radioactivity was determined in a 
Packard (Perkin Elmer, Zaventem, Belgium) Tri-Carb 2300 TR liquid scintillation counter. All 
radiolabeled materials were obtained from Moravek (Brea, CA).  
Enzyme assay with herpes simplex virus type 1 (HSV-1) DNA polymerase and cellular DNA 
polymerases α and β 
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The reaction mixture (40 µl) for the HSV-1 DNA polymerase and cellular DNA polymerase α assays 
contained 4 µl of Premix (200 mM Tris.HCl pH 7.5; 2 mM DTT; 30 mM MgCl2), 4 µl of BSA (5 mg/ml), 
1.6 µl of activated calf thymus DNA (1.0 mg/ml), 0.8 µl of dCTP (5 mM), 0.8 µl of dATP (5 mM), 0.8 µl 
of dGTP (5 mM), 2 µl of radiolabeled [3H]dTTP (1 mCi/ml) (3.2 µM), 18 µl of H2O, and 4 µl of T-α-CNP 
at different serial concentrations (i.e., 200, 40, 8, 1.6, 0.32 µM). For testing the C-α-CNP analogue, 2 
µl [3H]dCTP (1 mCi/ml) and 0.8 µl unlabelled dTTP, dATP, and dGTP (5 mM) were used. For testing the 
A-α-CNP analogue, 2 µl [3H]dATP (1 mCi/ml) and 0.8 µl unlabeled dTTP, dCTP and dGTP (5 mM) were 
used. The reaction was started by the addition of 4 µl of recombinant HSV-1 DNA polymerase (kindly 
provided by M.W. Wathen, at that time at Pfizer, Kalamazoo, MI) or human cellular DNA polymerase 
α or β (Chimerix, Milwaukee, WI) (in 20 mM Tris.HCl pH 8.0; 1 mM DTT; 0.1 mM EDTA; 0.2 M NaCl; 
40% glycerol), and the reaction mixture was incubated for 60 minutes at 37°C. Then, 1 ml of ice-cold 
5% TCA in 0.02 M Na4P2O7.10 H2O was added to terminate the polymerization reaction. The 
consecutive steps (i.e. capture of the acid-insoluble precipitate onto filters, filter washing and 
scintillation counting) were done as described above. 
Enzyme assay with varicella-zoster virus (VZV) DNA polymerase 
The VZV DNA polymerase assay was as follows: the 50 µl-reaction mixture contained 6.4 mM HEPES, 
12 mM KCl, 25 mM NaCl, 5 mM MgCl2, 4.6 µg BSA, 2 mM CHAPS, 5 mM DTT, 5% glycerol, 1 µCi 
[3H]dTTP, 100 µM poly dA.oligo dT, and 5 µl of serial dilutions of T-α-CNP. The reaction was started 
by the addition (5 µl) of recombinant VZV DNA polymerase (kindly provided by M.W. Wathen) in 5 
mM HEPES and incubated for 60 min at 37°C. The termination of the enzyme reaction and all 
consecutive steps to quantify the [3H]dTTP incorporation into the template/primer were done as 
described above. 
X-ray crystallography 
HIV-1 RT for the structural study was expressed, purified, and cross-linked to a dsDNA 
template/primer using a previously described protocol (5).  A 27-mer template (5’-
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ATGGACGGCGCCCGAACAGGGACTGTG-3’) and a 20-mer primer (5’-ACAGTCCCTGTTCGGGCGCC-3’) 
were used for cross-linking with RT (5).  The primer was extended by catalytic incorporation of a 
ddGMP at the 3’-end of the primer by RT while crosslinking the template/primer at the Q258C 
position.  The complex was purified and crystallized using a previously described protocol (5).  The 
crystals were soaked with 2 mM T-α-CNP in the presence of 20 mM MgCl2 to obtain an RT/dsDNA/T-
α-CNP ternary complex.  The X-ray diffraction data for the complex was collected from one flash-
frozen crystal at the CHESS F1 beamline.  The structure was solved by molecular replacement using 
the protein model from the RT/dsDNA/AZT-TP structure (PDB ID 3V4I).  The position and 
conformation of T-α-CNP was defined by difference electron density.  The final model of 
RT/dsDNA/T-α-CNP complex was refined at 2.9 Å resolution to an R and R-free of 0.199 and 0.251. 
The crystallographic software packages HKL2000, Phenix, and Coot were used for data processing, 
structure refinement, and model building, respectively.  The diffraction data and refinement statistics 
are summarized in Table S3, and the structure is deposited in the Protein Data Bank (PDB) with 
accession number 4R5P. 
Thymidine kinase assay 
The assay was performed as follows: The recombinant cytosolic thymidine kinase (TK-1), 
mitochondrial TK-2, HSV-1 TK, and VZV TK were incubated at 37°C for 30 min in the presence of 
different concentrations of the test compounds T-α-CNP, C-α-CNP, A-α-CNP and dTTP in a 50-μl-
reaction mixture containing 50 mM Tris-HCl (pH 8.0), 2.5 mM MgCl2, 10 mM dithiothreitol, 0.5 mM 
CHAPS, 3 mg/ml bovine serum albumin, 2.5 mM ATP, and a variety of different concentrations of 
[methyl-3H]deoxythymidine ([methyl-3H]dThd). After the incubation time, 45-μl aliquots of the 
reaction mixtures were spotted on Whatman DE-81 (anion exchange) filter paper disks. The filters 
were washed three times for 5 min in 1 mM ammonium formate, once for 1 min in water, and once 
for 5 min in ethanol. The radioactivity was determined by scintillation counting. 
dCMP deaminase assay 
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The effect of C-α-CNP on the activity of recombinant human dCMP-deaminase (dCMPD; Prospec, NJ) 
was evaluated. Deamination of dCMP (25, 50, 75, and 100 µM) by dCMPD (250 pg/µL) was assayed in 
100 µL of 50 mM Tris.HCl pH 7.5, containing different concentrations of C-α-CNP (625, 250, 125, and 
0 µM), dCTP (250 µM), MgCl2 (5 mM), and DMSO (5%). After 10 min incubation at 37°C, the reaction 
was stopped by the addition of 200 µL ice-cold MeOH. Samples were kept on ice for 10 min and 
subsequently cleared by centrifugation at 16,000 x g for 15 min. The supernatant was analyzed by 
HPLC (Alliance 2690; Waters, Milford, MA) using a Partisphere-SAX anion exchange column (5.6 x 125 
mm, Whatman International Ltd., Maidstone, UK). The following gradient was used to separate 
dCMP (RT = 4.2 min) from dUMP (RT = 7.4 min): 5 min at 100% buffer B (5 mM NH4H2PO4 pH 5); a 15 
min linear gradient of 100% buffer B to 100% buffer C (300 mM NH4H2PO4 pH 5); 10 min at 100% 
buffer C; a 5 min linear gradient to 100% buffer B; equilibration at 100% buffer B for 5 min. 
CMP/UMP kinase assay 
The reaction mixture (300 µl) consisted of reaction buffer (Tris.HCl 50 mM, MgCl2 5 mM, pH 7.5) to 
which was added 100 µM U-α-CNP or C-α-CNP, or 100 µM of the natural substrates UMP or CMP 
(included as reaction substrate controls), 5 mM ATP as phosphate donor, and recombinant 
CMP/UMP kinase (6) to initiate the CMP/UMP kinase reaction at 37°C. At 0, 15, 30, 120 min and 24 
hr, 100 µl of the reaction mixture was withdrawn, added to 200 µl ice-cold methanol and kept on ice 
for 10 min. Then, the methanol-insoluble material was removed by centrifugation and the 
supernatant subjected to HPLC analysis on a Partisyl SAX column (Hichrom (125 x 4.6 mm), Reading, 
Berkshire, UK) to separate and quantify the reaction products. 
NDP kinase assay 
The reaction mixture (400 µl) consisted of phosphate-buffered saline (PBS) containing 100 µM of T- 
α-CNP, C-α-CNP or A-α-CNP, or 200 µl of the natural substrates dTDP, CDP or ADP (included as 
reaction controls), 200 µM ATP as phosphate donor, 1 mM MgCl2 and recombinant NDPK (Sigma-
Aldrich, St. Louis, Mo) to initiate the NDPK reaction at 37°C. At 0, 30 and 60 min, 100 µl of the 
reaction mixture was withdrawn, added to 200 µl ice-cold methanol and kept on ice for 10 min. Then, 
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the methanol-insoluble material was removed by centrifugation and the supernatant subjected to 
HPLC analysis on a Partisyl SAX column to separate and quantify the reaction products. 
Cellular assays 
The antiproliferative (cytostatic) activity determination of the α-CNPs was performed as follows: to 
each well of a 96-well microtiter plate were added an appropriate amount of human CD4+ T-
lymphocyte CEM or cervix carcinoma HeLa cells and a 5-fold dilution series of the test compounds 
(highest concentration tested: 200 µM). The cells were allowed to proliferate for 72 hr (CEM) or 96 hr 
(HeLa) at 37°C in a humidified CO2-controlled atmosphere. At the end of the incubation period, the 
cells were counted in a Coulter counter (Coulter Electronics Ltd., Harpenden, Herts, UK). 
 The cytotoxic activity determination of the α-CNPs was performed as follows: confluent 
(human lung fibroblast HEL or cervix carcinoma HeLa) cell cultures in 96-well microtiter wells were 
exposed to a 5-fold dilution series of the test compounds (highest concentration tested: 200 µM). 
After a 3 day incubation period at 37°C, microscopically visible alteration of cell morphology was 
examined.  
The antiherpes virus [herpes simplex virus type 1 (HSV-1) (KOS); HSV-2 (G)] assays were 
based on inhibition of virus-induced cytopathicity in HEL cell cultures. Confluent HEL cell cultures in 
microtiter 96-well plates were inoculated with 100 CCID50 of virus (1 CCID50 being the virus dose to 
infect 50% of the cell cultures). The cell cultures were incubated at the time of infection in the 
presence of varying concentrations (200, 40, 8, 1.6 and 0.32 μM) of the test compounds. Viral 
cytopathicity was recorded microscopically as soon as it reached completion in the control virus-
infected cell cultures that were not treated with the test compounds. The methodology of the anti-
HIV assays was as follows: human CEM cells (~ 3 × 105 cells/mL) were infected with 100 CCID50 of 
HIV(IIIB) or HIV-2(ROD)/mL and seeded in 200-μL wells of a microtiter plate containing appropriate 
dilutions of the test compounds. After 4 days of incubation at 37 °C, HIV-induced giant cell formation 
was examined microscopically. 
Kinetical analysis 
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The nature of the kinetic interaction of the T-α-CNP, AZTTP, and INDOPY-1 against HIV-1 RT and T-α-
CNP and dTTP against dThd kinase were analysed by the mixed model using a non-linear regression 
method available in GraphPad. The mixed model uses a general equation including competitive, 
uncompetitive and noncompetitive inhibition as special cases. Following equations were used: 
Vmax(app) = Vmax/[1+I/αKi]; Km(app) = Km.[1+I/Ki]/[1+I/αKi]; Y = Vmax(app).X/[Km(app)+X], in which X is substrate 
concentration; Y is enzyme activity; Vmax is maximum enzyme velocity; Km = Michaelis-Menten 
constant; I is inhibitor concentration; Ki = inhibition constant and α is a constant that determines the 
kinetic mechanism. When α = 1, kinetics are noncompetitive. When α is very large, the kinetic model 
approaches a competitive interaction; when α is very small (but greater than zero), the kinetic model 
approaches an uncompetitive interaction. The R2-value represents a parameter for the goodness of 
curve fit. 
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Fig. S1. The two-metal ion mechanism of DNA polymerase. The two conserved aspartates D705 and 
D882 have the E. coli DNA polymerase I numbering. The DNA polymerase active site features two 
metal cations that stabilize the transition state. Metal ion A activates the primer 3’-OH for a 
nucleophilic attack on the α-phosphate of the dNTP. Metal ion B plays the dual role of stabilizing the 
negative charge that builds up on the leaving oxygen and chelating one oxygen from each of the α-, 
β-, and γ-phosphates. Metal B helps to orient the phosphates appropriately for polymerization and 
facilitates the release of pyrophosphate, the catalytic reaction byproduct. The filled circles represent 
water molecules. This configuration also supports an extended version of this model that considers 
simultaneous deprotonation of the 3’-OH of the primer and protonation of the pyrophosphate 
leaving group (1). The figure is taken from Steitz (2). 
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Fig. S2. Kinetic plot analyses for inhibition of HIV-1 RT by T-α-CNP (panels A, B), the NRTI AZT-TP 
(panels C, D) and the NcRTI INDOPY-1 (panels E, F). Test compounds were evaluated in the presence 
of varying concentrations of radiolabeled [CH3-3H]dTTP substrate and a fixed template/primer poly 
rA.oligo dT concentration (panels A, C, E) or in the presence of varying concentrations of 
template/primer (poly rA.dT) and a fixed [CH3-3H]dTTP concentration (panels B, D, F). The kinetics are 
competitive-type for T-α-CNP, AZT-TP and INDOPY-1 in the presence of variable dTTP substrate 
concentrations. The kinetics are non-competitive-type for AZT-TP and close to uncompetitive-type 
for T-α-CNP and INDOPY-1 in the presence of variable template/primer concentrations. The data 
were analyzed using the mixed model inhibition of GraphPad (Table S2). 
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Fig. S3. Structural formulas of T-α-CNP, methylated T-α-CNPs and the acyclic T-butenyl-α-CNP. 
Methylated T-α-CNPs were evaluated as their D/L-enantiomeric mixtures (1:1).  
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Figure S4 Inhibition of DNA synthesis monitored in time-course experiments at different fixed dNTP 
concentrations, T50A DNA template/5’-radiolabeled P1 DNA primer and a fixed concentration of T-
, C-, and A-α-CNP, respectively. Strong and specific sites of inhibition (short oligonucleotide 
sequences) disappear over time, while other specific sites of inhibition (longer oligonucleotide 
sequences) appear over time (last three lane series). The second left lane series shows control 
reactions taken at different time points in the absence of α-CNPs. The most left lane series shows 
control reactions with the obligate DNA chain-terminating nucleotides ddGTP, ddTTP, ddCTP and 
ddATP. 
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Fig. S5. Ternary RT-template/primer-inhibitor complex formation in the presence of INDOPY-1. 
Specific INDOPY-1 binding to HIV-1 RT was analyzed with four different template/primer 
combinations that contain either a thymine, adenine, guanine, or cytosine nucleotide, downstream 
of the 3’-end of the primer. Complex formation with HIV-1 RT was monitored with increasing 
concentrations of INDOPY-1. Stable, heparin-resistant ternary complexes are observed in the 
presence of INDOPY-1, irrespective of the templating nucleobase. 
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Fig. S6. Site-specific footprinting for α-CNP interaction with HIV-1 RT and the template/primer. The 
precise position of HIV-1 RT on its template/primer was analyzed through Fe2+-mediated footprinting. 
Upon binding of the Fe2+ ion to the RNase H domain, the template is cut in a site-specific manner that 
enables the distinction between pre- and post-translocated complexes. Like the prototype NcRTI 
(INDOPY-1), increasing concentrations of C-α-CNP trap the HIV-1 RT as a post-translocated complex. 
Concentrations of approximately 6 µM of C-α-CNP were required to trap 50% of the complexed 
enzyme populations in the post-translocational state. 
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Fig. S7. Stereo view of the molecular interaction of T-α-CNP with HIV-1 reverse transcriptase. 
Superposition of RT/RNA-DNA/dATP structure (PDB ID 4PQU; in gray scale) on RT/dsDNA/T-α-CNP 
(yellow protein/DNA and green T-α-CNP) structure. Both the complexes were crystallized in similar 
condition and crystal lattice, and 2.51 Å structure 4PQU has both the catalytic Mg2+ ions (purple) 
present at the polymerase active site. The chelating oxygen atoms of α-, β-, and γ-phosphates are 
colored purple. Highly analogous chemical and geometrical environments at the polymerase active 
sites in both the structures suggest that like a dNTP, T-α-CNP binding to RT involves chelation to both 
the Mg2+ ions; the metal A is not observed in most of RT/dsDNA/dNTP (or analog) structures, due to 
presumably the missing 3’-OH at the DNA primer terminus.  The base-pairing, base stacking, and 
metal chelation interactions are conserved between T-α-CNP and a dNTP when bound to RT; 
however, the residue K65 that interacts with the γ-phosphate of dNTP is located away from T-α-CNP. 
The template/primer was designed to have an adenine nucleobase overhang for base-pairing with T-
α-CNP.  
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Fig. S8. Allosteric inhibition of thymidine kinase (TK) and 2’-deoxycytidylate deaminase (dCMPD) by 
α-CNP. Panel A. Exposure of the L-enantiomeric C- and A-α-CNPs to cytosolic TK-1, mitochondrial TK-
2, herpes simplex virus type 1 TK, and varicella-zoster virus TK at varying α-CNP concentrations. 
Panels B and C. Substrate versus velocity plots for the allosteric inhibition of TK-2 by the natural 
inhibitor Mg2+-dTTP and T-α-CNP using the mixed model inhibition of GraphPad (Fig. 3; Table S5). 
Panel D. 2’-Deoxycytidylate deaminase (dCMPD) activity at varing dCMP substrates in the presence of 
a fixed concentration (250 µM) of the natural allosteric inhibitor dCTP. Km for dCMP was calculated to 
be ∼120 µM. Panel E. Inhibitory effect of the L-enantiomeric C-α-CNP on the allosteric stimulation of 
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dCMPD by dCTP. Varying concentrations of C-α-CNP were exposed to the enzyme for 10 min in the 
presence of different dCMP concentrations (25 to 100 µM) in the presence of one fixed Mg2+-dCTP 
(250 µM) concentration. The stimulatory effect of dCTP on dCMPD was dose-dependently inhibited 
by C-α-CNP. Data are the mean ± SD of at least 2 to 3 independent experiments. 
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Table S1. Inhibitory activity of the L-enantiomeric α-CNPs against HIV-1 RT in the presence of 
different homopolymeric template/primers 
Compounda IC50b HIV-1 reverse transcriptase (µM) 
 poly rA.dT 
([3H]dTTP) 
poly rI.dC 
([3H]dCTP) 
poly rU.dA 
([3H]dATP) 
T-α-CNP 0.41 ± 0.08 >500 155 ± 147 
U-α-CNP 3.0 ±1.6 >500 208 ± 72 
C-α-CNP 164 ± 22 4.3 ± 0.3 45 ± 0 
A-α-CNP >500 >500 0.19 ± 0.11 
AZT-TP 0.11 ± 0.05 - - 
ddCTP - 14 ± 1 - 
ddATP - - 1.5 ± 0.24 
 
aEach α-CNP represents as a pair of diastereomers at the alpha-carboxy stereocenter. 
b50% Inhibitory concentration, or compound concentration required to inhibit polymerase activity by 
50%. Data are the mean ± SD of at least 2 to 4 independent experiments. 
Inhibition of RTs by T-, U-, C-, and A-α-CNP analogues was evaluated using the respective 
homopolymeric template/primers poly rA.dT (for T- and U-α-CNP), poly rI.dC (for C-α-CNP), and poly 
rU.dA (for A-α-CNP) and ∼1.25-2.5 µM of their appropriate corresponding dNTP substrates [CH3-
3H]dTTP (for T- and U-α-CNP), [5-3H]dCTP (for C-α-CNP), and [2,8-3H]dATP (for A-α-CNP). 
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Table S2. Kinetic parameters for T-α-CNP, AZT-TP and INDOPY-1 inhibition of HIV-1 RT as derived 
from non-linear regression analysis (GraphPad Prism 5). 
 
Mode of inhibition Ki
a
 (µM) Km
b (µM) Alpha-valuec R²-valued 
T-α-CNP / dTTPe Competitive 0.283 ± 0.050 6.03 ± 1.31 3.29 0.964 
      
T-α-CNP / Poly rA.oligo dTf Uncompetitive 0.330 ± 0.022 0.868 ± 0.089 0.691 0.983 
      
AZT-TP / dTTPe Competitive 0.015 ± 0.002 4.29 ± 0.34 ~1.27 x 1022 0.982 
      
AZT-TP / Poly rA.oligo dTf Non-competitive 0.003 ± 0.0003 0.688 ± 0.121 1.07 0.977 
      
INDOPY-1 / dTTPe Competitive 0.168 ± 0.025 2.10 ± 0.31 87.9 0.980 
      
INDOPY-1 / Poly rA.oligo dTf Uncompetitive 0.908 ± 0.043 1.87 ± 0.13 0.150 0.997 
 
a Ki, inhibition constant. 
b Km, Michaelis-Menten constant. 
c Alpha-value determines the most likely kinetic mechanism. 
d R2-value represents a parameter for the goodness of curve fit. 
e Varying dTTP and drug. 
f Varying Poly rA.oligo dT and drug. 
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Table S3. X-ray data and refinement statistics for the HIV-1 RT/ds DNA/T-α-CNP complex 
 
 HIV-1 RT/dsDNA/T-α-CNP 
PDB ID 4R5P 
Data collection 
Space group; Cell dimensions P21 
a, b, c (Å) 89.9, 134.0, 139.2 
    α, β, γ  (°) 90, 97.81, 90 
Resolution range (Highest resolution shell) in 
Å 
50 – 2.9 (2.95 – 2.90) 
Rmerge 0.107 (0.634) 
I / σ(I) 8.9 (1.9) 
Completeness (%) 99.6 (99.2) 
Redundancy 4.0 (3.4) 
Refinement 
Resolution (Å) 44 – 2.9 
Cut-off criteria  F ≤ 0  
No. reflections (Rfree set) 72,084 (2,151) 
Rwork / Rfree 0.199 (0.251) 
No. atoms refined 17,726 
  
Stereochemistry (RMSDs) 
  Bond lengths (Å) 0.01 
  Bond angles (°) 1.51 
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Table S4. Inhibitory activity of thymine, cytosine and adenine α-CNPs against mutant HIV-1 reverse transcriptases 
HIV-1 RT Fold decreased activity compared to wild-type RTa 
 Poly rA.dT + [3H]dTTP  Poly rI.dC + [3H]dCTP  Poly rU.dA + [3H]dATP 
 T-α-CNP  INDOPY-1  C-α-CNP INDOPY-1  A-α-CNP INDOPY-1 
M184V 16 7.1  11 >6.7  1.7 NAb 
Y115F 2.4 2.8  1.1 2.9  0.79 NA 
 
aRatio of IC50 mutant RT/IC50 wild-type RT. Values were derived from the mean of at least 3 independent experiments. 
bNot active. 
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Table S5. Kinetic parameters for dTTP and T-α-CNP inhibition of TK-2 as derived from non-linear 
regression analysis (GraphPad Prism 5) 
 Mode of inhibition Ki
a
 (µM) Km
b (µM) Alpha-valuec R²-valued 
dTTP / dThde Competitive 0.927 ± 0.068 1.33 ± 0.126 ~ 3.15 x 1016 0.991 
      
T-α-CNP / dThdf 
Non-competitive 
125 ± 9.9 2.64 ± 0.27 1.24 0.977 
 
a Ki, inhibition constant. 
b Km, Michaelis-Menten constant. 
c Alpha-value determines the most likely kinetic mechanism. 
d R2-value represents a parameter for the goodness of curve fit. 
e Varying the substrate dThd and dTTP. 
f Varying the substrate dThd and T-α-CNP. 
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Table S6. Comparative overview of the properties of α-CNP and other HIV RT inhibitor classes 
 α-CNPa NRTI/NtRTIb NNRTIc NcRTId (INDOPY-
1) 
Nucleos(t)ide 
structure 
Yes Yes No No 
Metabolic 
conversion 
required 
No Yes No No 
Enzyme inhibition 
versus dNTP 
substrate 
Competitive Competitive Non-competitive Competitive 
Binding to RT 
substrate-binding 
site 
Yes Yes No Yes 
Nature of the RT 
binding 
Mutually exclusive 
with dNTP, but 
coordinating with 
Mg2+ 
Mutually exclusive 
with dNTP, but 
coordinating with 
Mg2+ 
Mutually exclusive 
with dNTP and 
Mg2+ 
Mutually 
exclusive with 
dNTP and with 
Mg2+ 
Nucleobase-
specific binding to 
template 
Yes Yes No No (but better 
after T or C than 
after G or A) 
Binding location Post-translocation 
(N) sitee 
N site NNRTI-binding site N site 
DNA chain 
termination 
No Yes No No 
Selective for HIV-1 
RT 
No No Yes (HIV-1) No 
 
aα-Carboxy nucleoside phosphonate. 
bNucleos(t)ide RT inhibitor (e.g. zidovudine triphosphate or tenofovir diphosphate). 
cNon-nucleoside RT inhibitor (e.g. nevirapine or rilpivirine). 
dNucleoside competitive RT inhibitor (e.g. INDOPY-1). 
eT-α-CNP binds the RT/nucleic acid complex in its post-translocated conformation, analogous to the 
binding of a dNTP. In contrast, foscarnet (a pyrophosphate analogue) has shown to trap the pre-
translocated RT/nucleic acid complex (1). 
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